Local tumor control, visual acuity, and survival after hypofractionated stereotactic photon radiotherapy of choroidal melanoma in 212 patients treated between 1997 and 2007.

PURPOSE To evaluate long-term local tumor control, visual acuity, and survival after hypofractionated linear accelerator-based stereotactic photon radiotherapy in patients with choroidal melanoma. METHODS AND MATERIALS Between 1997 and 2007, 212 patients with choroidal melanoma unsuitable for ruthenium-106 brachytherapy or local resection were treated stereotactically at a linear accelerator with 6-MV photon beams at the Medical University of Vienna in five fractions over 7 days. Twenty-four patients received a total dose of 70 Gy (five fractions of 14 Gy), 158 a total dose of 60 Gy (five fractions of 12 Gy) and 30 patients a total dose of 50 Gy (five fractions of 10 Gy) applied on the 80% isodose. Ophthalmologic examinations were performed at baseline and every 3 months in the first 2 years, every 6 months until 5 years, and once a year thereafter until 10 years after radiotherapy. Assessment of visual acuity, routine ophthalmologic examinations, and measurement of tumor base dimension and height using standardized A-scan and B-scan echography were done at each visit. Funduscopy and fluorescein angiography were done when necessary to document tumor response. RESULTS Median tumor height and volume decreased from 4.8 mm and 270.7 mm3 at baseline to 2.6 mm and 86.6 mm3 at the last individual follow-up, respectively (p<0.001, p<0.001). Median visual acuity decreased from 0.55 at baseline to hand motion at the last individual follow-up (p<0.001). Local tumor control was 95.9% after 5 years and 92.6% after 10 years. Thirty-two patients developed metastatic disease, and 22 of these patients died during the follow-up period. CONCLUSION Hypofractionated stereotactic photon radiotherapy with 70 to 50 Gy delivered in five fractions in 7 days is sufficient to achieve excellent local tumor control in patients with malignant melanoma of the choroid. Disease outcome and vision are comparable to those achieved with proton beam radiotherapy. Decreasing the total dose below 60 Gy seems to be possible.

[1]  E. Gragoudas,et al.  Intraocular recurrence of uveal melanoma after proton beam irradiation. , 1992, Ophthalmology.

[2]  E. Gragoudas,et al.  Uveal melanoma: proton beam irradiation. , 2005, Ophthalmology clinics of North America.

[3]  H. Guss,et al.  Gamma knife radiosurgery for uveal melanomas: an 8-year experience. , 2000, Journal of neurosurgery.

[4]  R. Pötter,et al.  A noninvasive eye fixation and computer-aided eye monitoring system for linear accelerator-based stereotactic radiotherapy of uveal melanoma. , 2001, International journal of radiation oncology, biology, physics.

[5]  E. Gragoudas.  Proton beam irradiation of uveal melanomas: the first 30 years. The Weisenfeld Lecture. , 2006, Investigative ophthalmology & visual science.

[6]  R. Pötter,et al.  LINAC based stereotactic radiotherapy of uveal melanoma: 4 years clinical experience. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  A. Sahgal,et al.  Stereotactic radiotherapy in the treatment of juxtapapillary choroidal melanoma: 2-year follow-up. , 2009, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[8]  R. Glynn,et al.  Epidemiologic aspects of uveal melanoma. , 1988, Survey of ophthalmology.

[9]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.

[10]  P Gastaud,et al.  Results of proton therapy of uveal melanomas treated in Nice. , 1999, International journal of radiation oncology, biology, physics.

[11]  J. Fraumeni,et al.  Melanomas of the eye and other noncutaneous sites: epidemiologic aspects. , 1976, Journal of the National Cancer Institute.

[12]  D. Char,et al.  Ten-year follow-up of helium ion therapy for uveal melanoma. , 1998, American journal of ophthalmology.

[13]  R. Rees,et al.  Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis , 1997, Genes, chromosomes & cancer.

[14]  T. Boehringer,et al.  Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma. , 2001, International journal of radiation oncology, biology, physics.

[15]  A. Tarkkanen,et al.  Iodine brachytherapy as an alternative to enucleation for large uveal melanomas. , 2003, Ophthalmology.

[16]  D. Char,et al.  Uveal tumour resection , 2001, The British journal of ophthalmology.

[17]  R. Pötter,et al.  Fractionated stereotactic radiotherapy with linear accelerator for uveal melanoma — Preliminary vienna results , 1999, Strahlentherapie und Onkologie.

[18]  A. de Klein,et al.  Clinical and cytogenetic analyses in uveal melanoma. , 2006, Investigative ophthalmology & visual science.

[19]  E. Schuster,et al.  Long-term follow-up of Ru-106/Rh-106 brachytherapy for posterior uveal melanoma , 2000, Graefe's Archive for Clinical and Experimental Ophthalmology.

[20]  B. Damato,et al.  Endoresection of choroidal melanoma , 1998, The British journal of ophthalmology.

[21]  K. Jöckel,et al.  Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. , 2003, Cancer research.

[22]  B. Damato,et al.  Surgical Resection of Choroidal Melanoma , 2006 .

[23]  P. Rama,et al.  Gamma knife radiosurgery for uveal melanoma: 12 years of experience , 2008, British Journal of Ophthalmology.

[24]  A. Sahgal,et al.  Stereotactic radiotherapy for treatment of juxtapapillary choroidal melanoma: 3-year follow-up , 2009, British Journal of Ophthalmology.

[25]  N. Bornfeld,et al.  Endoresektion maligner Melanome der Uvea nach präoperativer stereotaktischer Einzeldosis-Konvergenzbestrahlung mit dem Leksell-Gamma-knife , 2002, Der Ophthalmologe.

[26]  R Pötter,et al.  A linac-based stereotactic irradiation technique of uveal melanoma. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  A. Sahgal,et al.  Stereotactic radiotherapy in the treatment of juxtapapillary choroidal melanoma: preliminary results. , 2004, International journal of radiation oncology, biology, physics.

[28]  P. Levendag,et al.  Effectiveness of fractionated stereotactic radiotherapy for uveal melanoma. , 2004, International journal of radiation oncology, biology, physics.

[29]  J. Gérard,et al.  Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays). , 2004, American journal of ophthalmology.

[30]  A. Sasco,et al.  Survival after proton-beam irradiation of uveal melanomas. , 2004, American journal of ophthalmology.

[31]  L. Desjardins,et al.  Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO). , 2006, International journal of radiation oncology, biology, physics.

[32]  R. Glynn,et al.  Relative survival rates after alternative therapies for uveal melanoma. , 1990, Ophthalmology.

[33]  B. Damato,et al.  Proton beam radiotherapy of choroidal melanoma: the Liverpool-Clatterbridge experience. , 2005, International journal of radiation oncology, biology, physics.

[34]  E. Gragoudas,et al.  Comparison of survival rates for patients with uveal melanoma after treatment with proton beam irradiation or enucleation. , 1985, American journal of ophthalmology.

[35]  C. Patterson,et al.  Prognostic factors in malignant melanoma of the choroid: a retrospective survey of cases occurring in Northern Ireland between 1965 and 1980. , 1986, Transactions of the ophthalmological societies of the United Kingdom.

[36]  R. Timmerman,et al.  Gamma-Knife-Based Stereotactic Radiosurgery for Uveal Melanoma , 2007, Stereotactic and Functional Neurosurgery.

[37]  E. van Limbergen,et al.  18 Years’ experience with high dose rate strontium-90 brachytherapy of small to medium sized posterior uveal melanoma , 2005, British Journal of Ophthalmology.

[38]  Y. Akine,et al.  Fractionated stereotactic radiotherapy for choroidal melanoma. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[39]  D. Char,et al.  Long-term follow-up after uveal melanoma charged particle therapy. , 1997, Transactions of the American Ophthalmological Society.

[40]  S. Packer,et al.  Iodine-125 radiation of posterior uveal melanoma. , 1987, Ophthalmology.

[41]  B. Damato,et al.  Cytogenetics of uveal melanoma: a 7-year clinical experience. , 2007, Ophthalmology.

[42]  Ann Schalenbourg,et al.  Eye retention after proton beam radiotherapy for uveal melanoma. , 2003, International journal of radiation oncology, biology, physics.

[43]  T L Phillips,et al.  15 years experience with helium ion radiotherapy for uveal melanoma. , 1997, International journal of radiation oncology, biology, physics.

[44]  E. Gragoudas,et al.  A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. , 2000, Archives of ophthalmology.

[45]  R. Liščák,et al.  Leksell gamma knife treatment of uveal melanoma. , 2002, Journal of neurosurgery.

[46]  C. Shields,et al.  Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. , 2000, Archives of ophthalmology.

[47]  B. Damato.  Developments in the management of uveal melanoma , 2004, Clinical & experimental ophthalmology.

[48]  B. Damato.  Treatment of primary intraocular melanoma , 2006, Expert review of anticancer therapy.

[49]  R. Pötter,et al.  Impact of a micromultileaf collimator on stereotactic radiotherapy of uveal melanoma. , 2003, International journal of radiation oncology, biology, physics.